Previous close | 0.6400 |
Open | 0.6040 |
Bid | 0.6480 x N/A |
Ask | 0.7120 x N/A |
Day's range | 0.6040 - 0.6600 |
52-week range | 0.4460 - 2.0400 |
Volume | |
Avg. volume | 336 |
Market cap | 85.98M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -55.7400 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LONDON, April 23, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on its business priorities.
LONDON, April 17, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of the Revised Agenda for its Annual General Meeting set to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the "2024 AGM") (the "Revised Agenda").
LONDON, April 15, 2024--Regulatory News: BenevolentAI (or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that following extensive discussions with Mr. Kenneth Mulvany, founder and former Chairman of BenevolentAI Limited and a Non-Executive Director of BenevolentAI, several resolutions will be put forward at the Company’s upcoming Annual General Meeting ("AGM") relating to the future membership of the board of the